Kynam Capital Management, LP
Kynam Capital Management, LP reported 34 holdings worth US$1.81B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Kynam Capital Management, LP reported 34 holdings worth US$1.81B as of Sep 30, 2026. Largest: Legend Biotech Corp., Celldex Therapeutics, Inc. and Syndax Pharmaceuticals, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 34
- Value as reported
- US$1.81B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Legend Biotech Corp. | 9.15M | US$182M | 10.1% |
| Celldex Therapeutics, Inc. | 5.07M | US$164M | 9.1% |
| Syndax Pharmaceuticals, Inc. | 8.15M | US$153M | 8.5% |
| Vaxcyte, Inc. | 2.61M | US$148M | 8.2% |
| Viridian Therapeutics, Inc. | 6.15M | US$127M | 7.0% |
| Cogent Biosciences, Inc. | 3.79M | US$121M | 6.7% |
| Travere Therapeutics, Inc. | 2M | US$118M | 6.5% |
| Vera Therapeutics, Inc. | 3M | US$96.9M | 5.4% |
| Beam Therapeutics Inc. | 3.93M | US$96.2M | 5.3% |
| CytomX Therapeutics, Inc. | 21.1M | US$57.5M | 3.2% |
| MBX Biosciences, Inc. | 935K | US$54.8M | 3.0% |
| Summit Therapeutics Inc. | 3M | US$50.7M | 2.8% |
| Relay Therapeutics, Inc. | 2.75M | US$49.7M | 2.7% |
| Cullinan Therapeutics, Inc. | 3.11M | US$47.8M | 2.6% |
| Immunocore Holdings plc | 1.38M | US$41.6M | 2.3% |
| Nurix Therapeutics, Inc. | 1.19M | US$28.3M | 1.6% |
| Burning Rock Biotech Ltd. | 1.24M | US$21.8M | 1.2% |
| BioCryst Pharmaceuticals, Inc. | 2.52M | US$21M | 1.2% |
| Surrozen, Inc. | 486K | US$15.6M | 0.87% |
| Sutro Biopharma, Inc. | 873K | US$14.1M | 0.78% |
| Xenon Pharmaceuticals Inc. | 280K | US$10.4M | 0.58% |
| Evommune, Inc. | 1.2M | US$9.91M | 0.55% |
| Prelude Therapeutics Incorporated | 2.31M | US$9.04M | 0.50% |
| Geron Corporation | 6.84M | US$8.41M | 0.47% |
| Parabilis Medicines, Inc. | 250K | US$8.07M | 0.45% |
| Alector, Inc. | 4.31M | US$7.97M | 0.44% |
| Amarin Corporation plc | 533K | US$6.93M | 0.38% |
| Harrow, Inc. | 125K | US$3.84M | 0.21% |
| Caribou Biosciences, Inc. | 2.5M | US$3.18M | 0.18% |
| Traws Pharma, Inc. | 84,400 | US$50,117 | <0.01% |
| Candel Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Insmed Incorporated | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related